{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:16:33Z","timestamp":1771488993935,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40258-023-00869-7","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T03:02:42Z","timestamp":1705978962000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-9972","authenticated-orcid":false,"given":"Karissa M.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana F.","family":"Audhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Feeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelagh M.","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"869_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.690021","volume":"12","author":"I Jakab","year":"2021","unstructured":"Jakab I, Whittington MD, Franklin E, et al. Patient and payer preferences for additional value criteria. Front Pharmacol. 2021;12: 690021.","journal-title":"Front Pharmacol"},{"issue":"4","key":"869_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","volume":"25","author":"PJ Neumann","year":"2022","unstructured":"Neumann PJ, Garrison LP, Willke RJ. The History and Future of the \u201cISPOR Value Flower\u201d: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25(4):558\u201365.","journal-title":"Value Health."},{"issue":"1","key":"869_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jval.2018.08.010","volume":"22","author":"FB Kristensen","year":"2019","unstructured":"Kristensen FB, Husereau D, Hui\u0107 M, et al. Identifying the need for good practices in health technology assessment: summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value Health. 2019;22(1):13\u201320.","journal-title":"Value Health."},{"issue":"2","key":"869_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]. Value in Health. 2018;21(2):131\u20139.","journal-title":"Value in Health."},{"issue":"35","key":"869_CR5","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2217\/fon-2019-0456","volume":"15","author":"T Lanitis","year":"2019","unstructured":"Lanitis T, Ambavane A, Zheng Y, Schlichting M, Phatak H. Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvals. Future Oncol. 2019;15(35):4057\u201367.","journal-title":"Future Oncol"},{"key":"869_CR6","unstructured":"Institute for Clinical and Economic Review (ICER). 2020-2023 Value Assessment Framework. Boston January 31, 2020 2020."},{"issue":"2","key":"869_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","volume":"24","author":"DN Lakdawalla","year":"2021","unstructured":"Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach. Value Health. 2021;24(2):244\u20139.","journal-title":"Value Health."},{"key":"869_CR8","unstructured":"Innovation and Value Initiative. Open-source value project. https:\/\/thevalueinitiative.org\/open-source-value-project\/. Accessed 12 Apr 2023."},{"issue":"1","key":"869_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-020-00449-0","volume":"14","author":"E van Overbeeke","year":"2021","unstructured":"van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA Representatives. Patient. 2021;14(1):119\u201328.","journal-title":"Patient"},{"issue":"1","key":"869_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-022-00413-6","volume":"6","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Audhya IF, Feeny D, Neumann P, Malone DC, Gooch KL. Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States. J Patient-Report Outcomes. 2022;6(1):1\u201313.","journal-title":"J Patient-Report Outcomes."},{"issue":"5","key":"869_CR11","first-page":"650","volume":"27","author":"J Shafrin","year":"2021","unstructured":"Shafrin J, Dennen S, Pednekar P, et al. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports. J Manag Care Spec Pharm. 2021;27(5):650\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"869_CR12","first-page":"1548","volume":"26","author":"DT Kruzikas","year":"2020","unstructured":"Kruzikas DT, Malone DC, Pham S, Reinsch TK, Akehurst R. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications. J Manag Care Spec Pharm. 2020;26(12):1548\u201357.","journal-title":"J Manag Care Spec Pharm"},{"key":"869_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.socscimed.2016.08.036","volume":"166","author":"H Mason","year":"2016","unstructured":"Mason H, van Exel J, Baker R, et al. From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. Soc Sci Med. 2016;166:205\u201313.","journal-title":"Soc Sci Med"},{"key":"869_CR14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40273-021-01067-w","volume":"39","author":"L Morrell","year":"2021","unstructured":"Morrell L, Buchanan J, Rees S, Barker RW, Wordsworth S. What aspects of illness influence public preferences for healthcare priority setting? A discrete choice experiment in the UK. Pharmacoeconomics. 2021;39:1443\u201354.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"869_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235666","volume":"15","author":"A Nicolet","year":"2020","unstructured":"Nicolet A, van Asselt AD, Vermeulen KM, Krabbe PF. Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands. PLoS ONE. 2020;15(7): e0235666.","journal-title":"PLoS ONE"},{"issue":"12","key":"869_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jval.2019.07.012","volume":"22","author":"V Reckers-Droog","year":"2019","unstructured":"Reckers-Droog V, van Exel J, Brouwer W. Equity weights for priority setting in healthcare: severity, age, or both? Value in Health. 2019;22(12):1441\u20139.","journal-title":"Value in Health."},{"issue":"2","key":"869_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/0272989X15619389","volume":"36","author":"D Rowen","year":"2016","unstructured":"Rowen D, Brazier J, Mukuria C, et al. Eliciting societal preferences for weighting QALYs for burden of illness and end of life. Med Decis Making. 2016;36(2):210\u201322.","journal-title":"Med Decis Making"},{"key":"869_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.socscimed.2014.11.022","volume":"124","author":"KK Shah","year":"2015","unstructured":"Shah KK, Tsuchiya A, Wailoo AJ. Valuing health at the end of life: A stated preference discrete choice experiment. Soc Sci Med. 2015;124:48\u201356.","journal-title":"Soc Sci Med"},{"key":"869_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10198-014-0657-6","volume":"17","author":"E Van de Wetering","year":"2016","unstructured":"Van de Wetering E, Van Exel N, Rose J, Hoefman R, Brouwer W. Are some QALYs more equal than others? Eur J Health Econ. 2016;17:117\u201327.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"869_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.healthpol.2009.01.005","volume":"91","author":"C Mitton","year":"2009","unstructured":"Mitton C, Smith N, Peacock S, Evoy B, Abelson J. Public participation in health care priority setting: a scoping review. Health Policy. 2009;91(3):219\u201328.","journal-title":"Health Policy"},{"issue":"3","key":"869_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.pcl.2015.03.008","volume":"62","author":"N Wein","year":"2015","unstructured":"Wein N, Alfano L, Flanigan KM. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am. 2015;62(3):723\u201342.","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"869_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"8","key":"869_CR23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759\u201364.","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"869_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121799","volume":"10","author":"AM Seferian","year":"2015","unstructured":"Seferian AM, Moraux A, Canal A, et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE. 2015;10(4): e0121799.","journal-title":"PLoS ONE"},{"issue":"5","key":"869_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jpeds.2014.07.006","volume":"165","author":"KT Mirski","year":"2014","unstructured":"Mirski KT, Crawford TO. Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis. J Pediatr. 2014;165(5):1008\u201310.","journal-title":"J Pediatr"},{"issue":"10","key":"869_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","volume":"60","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Edstr\u00f6m J, Buccella F, Kirschner J, Lochm\u00fcller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987\u201396.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"869_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213649","volume":"14","author":"H Landrum Peay","year":"2019","unstructured":"Landrum Peay H, Fischer R, Tzeng JP, et al. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS ONE. 2019;14(5): e0213649.","journal-title":"PLoS ONE"},{"issue":"5","key":"869_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40271-022-00574-y","volume":"15","author":"NL Crossnohere","year":"2022","unstructured":"Crossnohere NL, Fischer R, Vroom E, Furlong P, Bridges JF. A comparison of caregiver and patient preferences for treating duchenne muscular dystrophy. Patient-Patient-Centered Outcomes Res. 2022;15(5):577\u201388.","journal-title":"Patient-Patient-Centered Outcomes Res"},{"issue":"5","key":"869_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/mus.25411","volume":"55","author":"IL Hollin","year":"2017","unstructured":"Hollin IL, Peay HL, Apkon SD, Bridges JF. Patient-centered benefit\u2013risk assessment in Duchenne muscular dystrophy. Muscle Nerve. 2017;55(5):626\u201334.","journal-title":"Muscle Nerve"},{"issue":"5","key":"869_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","volume":"36","author":"HL Peay","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624\u201337.","journal-title":"Clin Ther"},{"issue":"4","key":"869_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health. 2011;14(4):403\u201313.","journal-title":"Value in Health."},{"issue":"6","key":"869_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","volume":"17","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Marshall DA, Hauber AB, Bridges JF. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):531\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"869_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang J-C, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22(2):157\u201360.","journal-title":"Value Health"},{"issue":"9","key":"869_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"869_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW de Bekker-Grob","year":"2012","unstructured":"de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145\u201372.","journal-title":"Health Econ"},{"key":"869_CR36","doi-asserted-by":"crossref","unstructured":"Arias E, Tejada-Vera B, Kochanek KD, Ahmad FB. Provisional life expectancy estimates for 2021. US Centers for Disease Control and Prevention. National Center for Health Statistics (U.S.) Vital Statistics Rapid Release. 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/118999.","DOI":"10.15620\/cdc:118999"},{"key":"869_CR37","unstructured":"Blakeslee L, Caplan Z, Meyer JA, Rabe MA, Roberts AW. Age and sex composition: 2020. Washington, DC; 2023. C2020BR-06."},{"key":"869_CR38","unstructured":"McElrath K, Marti M. Bachelor\u2019s degree attainment in the United States: 2005 to 2019. Washington, DC: U.S. Census Bureau; 2021. ACSBR-009."},{"key":"869_CR39","unstructured":"Shrider EA, Kollar M, Chen F, Semega J. Income and poverty in the United States: 2020. Washington, DC: U.S. Census Bureau; 2021. ACSBR-009."},{"issue":"5","key":"869_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jval.2017.12.026","volume":"21","author":"SM Bourke","year":"2018","unstructured":"Bourke SM, Plumpton CO, Hughes DA. Societal preferences for funding orphan drugs in the United Kingdom: an application of person trade-off and discrete choice experiment methods. Value Health. 2018;21(5):538\u201346.","journal-title":"Value Health."},{"issue":"5","key":"869_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40271-020-00433-8","volume":"13","author":"S dosReis","year":"2020","unstructured":"dosReis S, Butler B, Caicedo J, et al. Stakeholder-engaged derivation of patient-informed value elements. Patient. 2020;13(5):611\u201321.","journal-title":"Patient"},{"issue":"2","key":"869_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B","volume":"6","author":"A Williams","year":"1997","unstructured":"Williams A. Intergenerational equity: an exploration of the \u201cfair innings\u201d argument. Health Econ. 1997;6(2):117\u201332.","journal-title":"Health Econ"},{"issue":"1","key":"869_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40271-014-0109-5","volume":"8","author":"N Dragojlovic","year":"2015","unstructured":"Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, Lynd LD. Challenges in measuring the societal value of orphan drugs: insights from a Canadian stated preference survey. Patient. 2015;8(1):93\u2013101.","journal-title":"Patient"},{"key":"869_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4715","volume":"341","author":"AS Desser","year":"2010","unstructured":"Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341: c4715.","journal-title":"BMJ"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-023-00869-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:58:20Z","timestamp":1713283100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-023-00869-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1007\/s40258-023-00869-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"18 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Sarepta Therapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IA and KG are employees of Sarepta Therapeutics Inc (no grant number). KMJ, JD, and SMS are employees of Broadstreet HEOR, which received funds from Sarepta to conduct this study. DF, PN, and DCM received consulting fees related to this work. DF has a proprietary interest in Health Utilities Incorporated, Dundas, Ontario, Canada. HUInc. distributes copyrighted Health Utilities Index (HUI) materials and provides methodological advice on the use of HUI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests and Funding"}},{"value":"In the conduct of this study, survey respondents provided electronic click consent after reviewing study information, by agreeing to consent statements and proceeding to the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Survey respondents were informed that results may be published prior to providing consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"De-identified data and study materials are available from the corresponding author on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Fractional factorial design and analysis R code are available from the corresponding author on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"KJ, IA, JD, DF, PN, DM, SS, and KG conceived the study, interpreted the results, and prepared the manuscript. KJ, IA, JD, DF, PN, DM, SS, and KG developed\/reviewed the survey. KJ analyzed the data. All authors critically reviewed the manuscript and approved the final draft.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"This study received institutional review board (IRB) approval through Advarra, Inc. (Pro00052976). This study was performed in accordance with the Declaration of Helsinki\u2014Version 2008.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}